RNA stock

Atrium Therapeutics, Inc. Common Stock (RNA) financials · rev $18.8M

Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT

Atrium Therapeutics, Inc. Common Stock (RNA) rev $18.8M.

Cached annual income statement
LineFY2025FY2024
Revenue$18.8M$10.9M
Operating Income-$745.9M-$378.9M
Net Income-$684.6M-$322.3M
EPS (Diluted)-$4.97-$2.89
Cached annual balance sheet
LineFY2025FY2024
Total Assets$1.96B$1.56B
Current Assets$1.80B$1.54B
Cash & Equivalents$382.5M$219.9M
PP&E$23.3M$12.7M
Total Liabilities$269.4M$138.9M
Current Liabilities$195.4M$98.0M
Shareholders' Equity$1.69B$1.42B
Retained Earnings-$1.58B-$893.1M
Cached annual cash flow
LineFY2025FY2024
Operating Cash Flow-$650.4M-$300.9M
CapEx$13.3M$7.07M
Investing Cash Flow-$38.0M-$854.2M
Financing Cash Flow$851.0M$1.19B
Net Change in Cash$162.7M$37.3M
Free Cash Flow-$663.8M-$307.9M
These statements as JSON? API free 100/day

FAQ

What is RNA P/E and revenue?

Atrium Therapeutics, Inc. Common Stock (RNA) rev $18.8M.

What is RNA revenue?

Atrium Therapeutics, Inc. Common Stock last cached revenue is $18.8M (FY2025).

Is RNA profitable?

Atrium Therapeutics, Inc. Common Stock last cached net income is -$684.6M (FY2025).

What are RNA total assets?

Atrium Therapeutics, Inc. Common Stock last cached total assets are $1.96B (FY2025).

What is RNA free cash flow?

Atrium Therapeutics, Inc. Common Stock last cached free cash flow is -$663.8M (FY2025).

Not investment advice. Cached statements, not a live tape.